Andi Krumbholz

Humoral immunity to current variants of SARS-CoV-2 in exposed adults, September 2023 to September 2024

Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

SARS-CoV-2 rapid antigen test sensitivity and viral load in newly symptomatic hospital employees in Berlin, Germany, December, 2020 to February, 2022: an observational study

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests.

In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2

Magnipore: Prediction of differential single nucleotide changes in the Oxford Nanopore Technologies sequencing signal of SARS-CoV-2 samples

Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany

Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany.

Limited antibody response after BA.4-5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: Results of a case series.

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.

Limited antibody response after BA.4/5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: results of a case series

Diagnostic performance of a fully automated hepatitis E virus antibody immunoassay

Diagnostic performance of a fully automated hepatitis E virus antibody immunoassay

Humoral immune response after different SARS-CoV-2 vaccination regimens.

The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection.

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinations

Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccination

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Estimating infectiousness throughout SARS-CoV-2 infection course

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study

Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.

The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines